BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8534929)

  • 1. Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma.
    Teicher BA; Dupuis NP; Robinson MF; Emi Y; Goff DA
    Oncol Res; 1995; 7(5):237-43. PubMed ID: 8534929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models.
    Herbst RS; Takeuchi H; Teicher BA
    Cancer Chemother Pharmacol; 1998; 41(6):497-504. PubMed ID: 9554595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents.
    Kakeji Y; Teicher BA
    Invest New Drugs; 1997; 15(1):39-48. PubMed ID: 9195288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma.
    Teicher BA; Holden SA; Ara G; Korbut T; Menon K
    Cancer Chemother Pharmacol; 1996; 38(2):169-77. PubMed ID: 8616908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma.
    Teicher BA; Holden SA; Dupuis NP; Kakeji Y; Ikebe M; Emi Y; Goff D
    Breast Cancer Res Treat; 1995; 36(2):227-36. PubMed ID: 8534870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Host distribution and response to antitumor alkylating agents of EMT-6 tumor cells from subcutaneous tumor implants.
    Holden SA; Emi Y; Kakeji Y; Northey D; Teicher BA
    Cancer Chemother Pharmacol; 1997; 40(1):87-93. PubMed ID: 9137536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents.
    Teicher BA; Holden SA; Ara G; Sotomayor EA; Huang ZD; Chen YN; Brem H
    Int J Cancer; 1994 Jun; 57(6):920-5. PubMed ID: 7515861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased efficacy of chemo- and radio-therapy by a hemoglobin solution in the 9L gliosarcoma.
    Teicher BA; Dupuis NP; Emi Y; Ikebe M; Kakeji Y; Menon K
    In Vivo; 1995; 9(1):11-8. PubMed ID: 7669943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic drug interactions between angiogenic inhibitor, TNP-470 and anticancer agents in primary cultured hepatocytes and microsomes.
    Placidi L; Scott EC; Eckoff D; Bynon S; Sommadossi JP
    Drug Metab Dispos; 1999 May; 27(5):623-6. PubMed ID: 10220492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease.
    Teicher BA; Sotomayor EA; Huang ZD
    Cancer Res; 1992 Dec; 52(23):6702-4. PubMed ID: 1384969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma.
    Teicher BA; Sotomayor EA; Huang ZD; Ara G; Holden S; Khandekar V; Chen YN
    Cancer Chemother Pharmacol; 1993; 33(3):229-38. PubMed ID: 8269604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. cis-Diamminedichloroplatinum-resistant cell lines derived from human epithelial ovarian carcinoma express increased susceptibility to angiogenesis inhibitor TNP-470.
    Tamura M; Takakuwa K; Tanaka K
    Gynecol Oncol; 2004 Feb; 92(2):530-6. PubMed ID: 14766244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo.
    Sotomayor EA; Teicher BA; Schwartz GN; Holden SA; Menon K; Herman TS; Frei E
    Cancer Chemother Pharmacol; 1992; 30(5):377-84. PubMed ID: 1505076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo modulation of several anticancer agents by beta-carotene.
    Teicher BA; Schwartz JL; Holden SA; Ara G; Northey D
    Cancer Chemother Pharmacol; 1994; 34(3):235-41. PubMed ID: 8004757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the dosing schedule of TNP-470 [O-(chloroacetyl-carbamoyl) fumagillol] enhances its antitumor and antiangiogenic efficacies.
    Koyanagi S; Nakagawa H; Kuramoto Y; Ohdo S; Soeda S; Shimeno H
    J Pharmacol Exp Ther; 2003 Feb; 304(2):669-74. PubMed ID: 12538820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma.
    Teicher BA; Williams JI; Takeuchi H; Ara G; Herbst RS; Buxton D
    Anticancer Res; 1998; 18(4A):2567-73. PubMed ID: 9703911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies.
    Teicher BA; Korbut TT; Menon K; Holden SA; Ara G
    Cancer Chemother Pharmacol; 1994; 33(6):515-22. PubMed ID: 8137463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic and antitumor effects of tranilast on mouse lung carcinoma cells.
    Yatsunami J; Aoki S; Fukuno Y; Kikuchi Y; Kawashima M; Hayashi SI
    Int J Oncol; 2000 Dec; 17(6):1151-6. PubMed ID: 11078800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice.
    Newman MS; Colbern GT; Working PK; Engbers C; Amantea MA
    Cancer Chemother Pharmacol; 1999; 43(1):1-7. PubMed ID: 9923534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo/ex vivo and in situ assays used in cancer research: a brief review.
    Teicher BA
    Toxicol Pathol; 2009 Jan; 37(1):114-22. PubMed ID: 19098118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.